drugset / Trial / NCT03319901

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

NCT03319901

Phase 1/2 Active not recruiting 82 enrolled Dana-Farber Cancer Institute AbbVie · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine

Timeline

Start
2017-10-30
Primary completion
2025-11-25
Completion
2028-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule 400 mg Oral
Subject Venetoclax Small molecule 600 mg Oral
Background Cyclophosphamide Other / unclassified
Background Cytarabine Small molecule
Background Dexamethasone Small molecule
Background Doxorubicin Other / unclassified
Background Etoposide Small molecule
Background MERCAPTOPURINE ANHYDROUS Small molecule
Background Methotrexate Small molecule
Background Vincristine Small molecule

Indications